Kuznicki Law is investigating the proposed merger of Vascular Biogenics Ltd. operating as VBL Therapeutics, (the “Company”) (NasdaqGM: VBLT) with Notable Labs, Inc. Under the terms of the proposed transaction, Vascular shareholders will end up owning approximately 24% of the combined company, each on a fully-diluted basis and subject to adjustment. Kuznicki Law is seeking to determine whether the merger and the process that led to it are adequate, or whether the merger undervalues the Company.
Vascular Biogenics Ltd. (NasdaqGM: VBLT) Loss Submission Form
If you would like to discuss your legal rights regarding this case, you may, without obligation or cost to you, contact us toll free at (833) 835-1495 or fill out the loss submission form on this page.